» Articles » PMID: 16782892

Regulated Activating Thr172 Phosphorylation of Cyclin-dependent Kinase 4(CDK4): Its Relationship with Cyclins and CDK "inhibitors"

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2006 Jun 20
PMID 16782892
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin-dependent kinase 4 (CDK4) is a master integrator of mitogenic and antimitogenic extracellular signals. It is also crucial for many oncogenic transformation processes. Various molecular features of CDK4 activation remain poorly known or debated, including the regulation of its association with D-type cyclins, its activating Thr172 phosphorylation, and the roles of Cip/Kip CDK "inhibitors" in these processes. Thr172 phosphorylation of CDK4 was reinvestigated using two-dimensional gel electrophoresis in various experimental systems, including human fibroblasts, canine thyroid epithelial cells stimulated by thyrotropin, and transfected mammalian and insect cells. Thr172 phosphorylation of CDK4 depended on prior D-type cyclin binding, but Thr172 phosphorylation was also found in p16-bound CDK4. Opposite effects of p27 on cyclin D3-CDK4 activity observed in different systems depended on its stoichiometry in this complex. Thr172-phosphorylated CDK4 was enriched in complexes containing p21 or p27, even at inhibitory levels of p27 that precluded CDK4 activity. Deletion of the p27 nuclear localization signal sequence relocalized cyclin D3-CDK4 in the cytoplasm but did not affect CDK4 phosphorylation. Within cyclin D3 complexes, T-loop phosphorylation of CDK4, but not of CDK6, was directly regulated, identifying it as a determining target for cell cycle control by extracellular factors. Collectively, these unexpected observations indicate that CDK4-activating kinase(s) should be reconsidered.

Citing Articles

Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI/SNF loss-of-function tumors.

Wang X, Wang Y, Xie M, Ma S, Zhang Y, Wang L Cell Death Dis. 2024; 15(11):794.

PMID: 39500892 PMC: 11538500. DOI: 10.1038/s41419-024-07109-3.


Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition.

Lin C, Sniezek C, McGann C, Karki R, Giglio R, Garcia B bioRxiv. 2024; .

PMID: 38853901 PMC: 11160595. DOI: 10.1101/2024.05.23.592075.


CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.

Pita J, Raspe E, Coulonval K, Decaussin-Petrucci M, Tarabichi M, Dom G Front Endocrinol (Lausanne). 2023; 14:1247542.

PMID: 37964967 PMC: 10641312. DOI: 10.3389/fendo.2023.1247542.


CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges.

Arsenijevic T, Coulonval K, Raspe E, Demols A, Roger P, Van Laethem J Cancers (Basel). 2023; 15(3).

PMID: 36765923 PMC: 9913743. DOI: 10.3390/cancers15030968.


An Activity-Based Oxaziridine Platform for Identifying and Developing Covalent Ligands for Functional Allosteric Methionine Sites: Redox-Dependent Inhibition of Cyclin-Dependent Kinase 4.

Gonzalez-Valero A, Reeves A, Page A, Moon P, Miller E, Coulonval K J Am Chem Soc. 2022; 144(50):22890-22901.

PMID: 36484997 PMC: 10124963. DOI: 10.1021/jacs.2c04039.


References
1.
Harper J, Elledge S, Keyomarsi K, Dynlacht B, Tsai L, Zhang P . Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995; 6(4):387-400. PMC: 301199. DOI: 10.1091/mbc.6.4.387. View

2.
Sherr C, Roberts J . Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9(10):1149-63. DOI: 10.1101/gad.9.10.1149. View

3.
Sherr C, Roberts J . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13(12):1501-12. DOI: 10.1101/gad.13.12.1501. View

4.
Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M . Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 2001; 20(23):6637-47. PMC: 125323. DOI: 10.1093/emboj/20.23.6637. View

5.
Hall M, Bates S, Peters G . Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene. 1995; 11(8):1581-8. View